Discounted Cash Flow (DCF) Analysis Levered
Interpace Biosciences, Inc. (IDXG)
$1.05
-0.03 (-2.78%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 15.90 | 21.90 | 24.08 | 32.40 | 41.31 | 52.65 | 67.10 | 85.52 | 108.99 | 138.90 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -15.26 | -8.67 | -18.96 | -13.98 | -8.72 | -29.34 | -37.39 | -47.65 | -60.73 | -77.39 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.03 | -0.45 | -0.13 | -1.57 | -0.35 | -0.89 | -1.14 | -1.45 | -1.85 | -2.36 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -15.29 | -9.12 | -19.09 | -15.55 | -9.07 | -30.23 | -38.53 | -49.10 | -62.58 | -79.75 |
Weighted Average Cost Of Capital
| Share price | $ 1.05 |
|---|---|
| Beta | 0.821 |
| Diluted Shares Outstanding | 4.13 |
| Cost of Debt | |
| Tax Rate | 3.05 |
| After-tax Cost of Debt | 6.51% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 7.530 |
| Total Debt | 13.72 |
| Total Equity | 4.34 |
| Total Capital | 18.06 |
| Debt Weighting | 75.96 |
| Equity Weighting | 24.04 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 15.90 | 21.90 | 24.08 | 32.40 | 41.31 | 52.65 | 67.10 | 85.52 | 108.99 | 138.90 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.26 | -8.67 | -18.96 | -13.98 | -8.72 | -29.34 | -37.39 | -47.65 | -60.73 | -77.39 |
| Capital Expenditure | -0.03 | -0.45 | -0.13 | -1.57 | -0.35 | -0.89 | -1.14 | -1.45 | -1.85 | -2.36 |
| Free Cash Flow | -15.29 | -9.12 | -19.09 | -15.55 | -9.07 | -30.23 | -38.53 | -49.10 | -62.58 | -79.75 |
| WACC | ||||||||||
| PV LFCF | -28.32 | -33.81 | -40.37 | -48.19 | -57.53 | |||||
| SUM PV LFCF | -208.22 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 6.75 |
| Free cash flow (t + 1) | -81.35 |
| Terminal Value | -1,712.61 |
| Present Value of Terminal Value | -1,235.43 |
Intrinsic Value
| Enterprise Value | -1,443.65 |
|---|---|
| Net Debt | 10.65 |
| Equity Value | -1,454.30 |
| Shares Outstanding | 4.13 |
| Equity Value Per Share | -351.71 |